Compare Ecopetrol SA (EC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs IDEXX Laboratories, Inc. — how do they compare? Ecopetrol SA trades at $15.94 (market cap $30.44B), while IDEXX Laboratories, Inc. trades at $576.84 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Ecopetrol SA pays a 4.06% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| EC | IDXX | |
|---|---|---|
Market Cap | $30.44B | $43.94B |
Sector | Energy | Health |
52-Week High | $16.58 | $766.68 |
52-Week Low | $8.29 | $514.61 |
Enterprise Value | $58.23B | $44.84B |
Dividend Yield | 4.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $15.93, down 1.42% with mixed technical signals showing bullish moving averages but bearish oscillators. The company maintains solid profitability with 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6B in 2022 to $119.7B in 2025. Recent developments include a collective bargaining agreement with workers and upcoming Q2 2026 earnings release on August 3, 2026.
While valuation appears reasonable with P/E of 11.39, declining revenue trends and recent earnings misses pose challenges. Analyst consensus is cautious with 54.55% hold rating and $14.63 price target below current levels. Key risks include oil price volatility and execution challenges in a competitive energy sector.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
